Cargando…
Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer
Because both vindesine and gemcitabine are active drugs in advanced non-small-cell lung cancer (NSCLC), with different modes of action and only partly overlapping toxicity, a phase II study was performed. Gemcitabine 1000 mg m(−2) was given on days 1, 8 and 15 every 4 weeks, while vindesine 3 mg m(−...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
1999
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362682/ https://www.ncbi.nlm.nih.gov/pubmed/10070884 http://dx.doi.org/10.1038/sj.bjc.6690140 |